Allelic frequency of PON1 Q192R, CYP2C19*2 and CYP2C19*17 among Jordanian patients taking clopidogrel

被引:5
|
作者
Rjoub, Malek [1 ]
Saleh, Akram [2 ]
Hakooz, Nancy [3 ]
Imraish, Amer [4 ]
Jarrar, Yazun [5 ]
Zihlif, Malek [1 ]
机构
[1] Univ Jordan, Fac Med, Dept Pharmacol, Amman, Jordan
[2] Univ Jordan, Dept Internal Med, Univ Jordan Hosp, Amman, Jordan
[3] Univ Jordan, Dept Biopharmaceut & Clin Pharm, Fac Pharm, Amman, Jordan
[4] Univ Jordan, Dept Biol, Fac Sci, Amman, Jordan
[5] AlZaytoonah Univ Jordan, Coll Pharm, Dept Pharm, Amman, Jordan
关键词
CYP2C9; polymorphisms; Clopidogrel; Genotype; Allele frequency; PON1; genes; GENETIC-POLYMORPHISM; GENOTYPE FREQUENCIES; CYP2C19; PHARMACOGENETICS; PARAOXONASE-1; PHENOTYPE; VARIANT; 2C19;
D O I
10.4314/tjpr.v17i11.24
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the influence of allelic frequencies of PON1 Q192R, CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the response to clopidogrel among Jordanian patients. Methods: Polymorphisms in CYP2C19 were assessed among 148 patients using PCR-RFLP assay. Results: The CYP2C19*2, CYP2C19*17, and PON1 Q192R allele frequencies were 9.8, 28.72 and 28.7 %, respectively. On the genotyping side, the frequencies of CYP2C19*1/1* and CYP2C19*1/2* were 80.4 and 19.6 %, respectively, but none of the patients had CYP2C19*2/2* genotype. The genotype frequencies CYP2C19*17 were 47.97, 46.62 and 5.41 % for wild-type C-C, heterozygote C-T, and the mutant T-T, respectively. PON1 genotype was 42.7 % for QQ, and 57.8 % for QR. None of the patients had RR genotype. Conclusion: Relative to other populations, the observed allelic frequencies are consistent with the values reported for Caucasian and Middle Eastern populations.
引用
收藏
页码:2275 / 2280
页数:6
相关论文
共 50 条
  • [1] Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome
    Peng, Wenxing
    Shi, Xiujin
    Xu, Xiaoyu
    Lin, Yang
    CARDIOVASCULAR THERAPEUTICS, 2019, 2019
  • [2] Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention
    Chen Yu
    Huang Xiaohong
    Tang Yong
    Xie Yuquan
    Zhang Yachen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C203 - C203
  • [3] Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention
    Chen, Yu
    Huang, Xiaohong
    Tang, Yong
    Xie, Yuquan
    Zhang, Yachen
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (06): : 9266 - 9274
  • [4] Positive Clinical Response to Clopidogrel is Independent of Paraoxonase 1 Q192R and CYP2C19 Genetic Variants
    Martinez-Quintana, Efren
    Medina-Gil, Jose M.
    Rodriguez-Gonzalez, Fayna
    Garay-Sanchez, Paloma
    Liminana, Jose M.
    Saavedra, Pedro
    Tugores, Antonio
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (08): : 843 - 849
  • [5] Effect of PON1 and CYP2C19 genetic variants on the pharmacokinetics and pharmacodynamics of clopidogrel
    Hulot, J-S.
    Collet, J-P.
    Cayla, G.
    Sylvain, J.
    Finzi, J.
    Allanic, F.
    Bellemain-Appaix, A.
    Anzaha, G.
    Montalescot, G.
    EUROPEAN HEART JOURNAL, 2011, 32 : 341 - 342
  • [6] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [7] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [8] Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
    Daniele Jones
    Shana Persad-Ramdeensingh
    Sheherazade Crystal Abrahim
    Naveen Seecheran
    Rajini Rani Haraksingh
    Cardiology and Therapy, 2024, 13 : 191 - 203
  • [9] Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
    Jones, Daniele
    Persad-Ramdeensingh, Shana
    Abrahim, Sheherazade Crystal
    Seecheran, Naveen
    Haraksingh, Rajini Rani
    CARDIOLOGY AND THERAPY, 2024, 13 (01) : 191 - 203
  • [10] The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19☆2 genotyping
    Langaee, Taimour Y.
    Zhu, Hao-Jie
    Wang, Xinwen
    El Rouby, Nihal
    Markowitz, John S.
    Goldstein, Joyce A.
    Johnson, Julie A.
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (08): : 381 - 386